Skip to main content

Aortic Valve Disease

Cardiovascular
2
Pipeline Programs
14
Companies
35
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Cardiovascular is a $69.4B mature market dominated by anticoagulants and metabolic therapies with stable blockbuster portfolios.

$69.4B marketMature→ Stable30 products15 companies

Key Trends

  • FXa inhibitors (ELIQUIS, XARELTO) command 62% of market spending, creating limited room for new entrants
  • SGLT2 inhibitors gaining traction in heart failure indication, signaling expansion beyond traditional anticoagulation
  • Multiple patent cliffs (JANUVIA 2027, OPSUMIT 2029) create near-term revenue vulnerability but reinvestment pressure

Career Verdict

Strong choice for commercial, clinical operations, and device integration roles; limited opportunity for innovative pipeline development given market maturity.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Peak15.0yr
#2JARDIANCEGrowing
$8.8B
Boehringer Ingelheim·Peak8.6yr
#3XARELTOStable
$6.3B
Johnson & Johnson·Peak
#4FARXIGAGrowing
$4.3B
AstraZeneca·Peak15.4yr
#5JANUVIADeclining
$4.1B
Merck & Co.·LOE_Approaching1.0yr

Drug Class Breakdown

FXa Inhibitors (Apixaban/Rivaroxaban)
$42.8B(62%)

Mature, stable revenue base

SGLT2 Inhibitors
$13.1B(19%)

Growing in heart failure and renal indications

DPP4 Inhibitors
$4.1B(6%)

Declining as LOE approaches 2027

ARBs and Combination Therapies
$3.4B(5%)

Stable in heart failure management

Endothelin Receptor Antagonists and Prostacyclin Agonists
$1.8B(3%)

Niche pulmonary hypertension market

Career Outlook

Stable

Cardiovascular careers are stable but not expanding; the market is mature, dominated by blockbuster franchises with predictable commercial cycles and patent cliffs. Professionals entering this space should expect strong compensation (Commercial $210K avg, Medical Affairs $201K avg) but limited opportunity to drive breakthrough innovation. Device company roles offer better growth trajectories than pharma, particularly in remote monitoring, diagnostics, and patient engagement technologies.

Breaking In

Target device companies (Abbott, Medtronic) for growth potential; if joining pharma, focus on Commercial or Clinical Operations roles where hiring is active and compensation is competitive.

For Experienced Professionals

Leverage cardiovascular expertise to move into medical device strategy, digital health partnerships, or adjacent therapeutic areas; R&D opportunity is limited and may require lateral moves to access innovation-focused roles.

In-Demand Skills

Healthcare economics and payer management (anticoagulation safety monitoring, cost-effectiveness)Real-world evidence generation (postmarket surveillance for FXa inhibitors)Digital health and remote patient monitoring integrationClinical trial execution in large, established patient populationsRegulatory expertise in label expansions (SGLT2 inhibitor indications)

Best For

Commercial/Sales roles (mature market execution)Medical Science Liaisons (managing healthcare provider relationships on established therapies)Clinical Operations/Project Managers (managing large Phase 3/4 programs)Regulatory Affairs (label expansion strategy, patent cliff preparation)Health Economics and Outcomes Research (demonstrating value in competitive anticoagulation market)

Hiring Landscape

$130K-$210K

Cardiovascular hiring is concentrated in device companies (Abbott 337, Medtronic 317) rather than pharma, reflecting the therapeutic area's reliance on hardware solutions and patient management infrastructure. Pharma hiring (Johnson & Johnson 261, Bristol Myers Squibb 52) is heavily weighted toward Commercial (468 roles) and Clinical Operations (296 roles), with minimal R&D investment (14 roles). Medical device integration and remote patient monitoring expertise are increasingly valued as the market consolidates.

1,386
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

Abbott
337Growing
Medtronic
317Growing
Johnson & Johnson
261Stable
Bristol Myers Squibb
52Declining
Edwards Lifesciences
78Growing

By Department

Commercial(34%)
$210K
Clinical Operations(21%)
$180K
Engineering(13%)
$145K
Medical Affairs(1%)
$201K
Research & Development(1%)
$194K

Device companies offer more growth opportunities; pharma roles are high-paying but oriented toward mature market execution rather than innovation.

Competitive Landscape

13 companies ranked by most advanced pipeline stage

Edwards Lifesciences
13 programs
1
AspirinPhase 41 trial
EDWARDS INTUITYN/A1 trial
EDWARDS INTUITY Elite Valve SystemN/A1 trial
EDWARDS INTUITY Valve System FOUNDATION StudyN/A1 trial
EDWARDS INTUITY Valve System, Model 8300AN/A1 trial
+8 more programs
Active Trials
NCT02688153Completed120Est. Apr 2016
NCT02907463Completed280Est. Dec 2017
NCT02338154Completed516Est. Apr 2016
+10 more trials
Artivion
ArtivionKENNESAW, GA
1 program
1
On-X Aortic Mechanical ValvePhase 31 trial
Active Trials
NCT04142658Terminated863Est. Dec 2022
Abbott
AbbottABBOTT PARK, IL
6 programs
Aortic Valve ReplacementN/A1 trial
Artificial Mechanical Heart ValveN/A1 trial
PAR I - Patient-to-Annulus Relation IN/A1 trial
Trifecta GTN/A1 trial
Trifecta™ aortic bioprosthesisN/A1 trial
+1 more programs
Active Trials
NCT03924661Active Not Recruiting20Est. Oct 2028
NCT00590889Terminated807Est. Sep 2014
NCT02981004Completed304Est. Dec 2017
+3 more trials
Corcym
CorcymUK - London
4 programs
Aortic Valve Replacement with Perceval S sutureless heart valveN/A1 trial
Perceval S sutureless heart valveN/A1 trial
Perceval valveN/A1 trial
Sorin Universal REgistry on Aortic Valve ReplacementN/A1 trial
Active Trials
NCT03481387Unknown61Est. Feb 2024
NCT06011148Unknown80Est. Dec 2025
NCT02673697Terminated914Est. Jul 2020
+1 more trials
MicroPort
MicroPortChina - Shanghai
2 programs
MicroPort's Transcatheter Aortic Valve and Delivery SystemN/A1 trial
VitaFlow® Transcatheter Aortic Valve Replacement SystemN/A1 trial
Active Trials
NCT02221921Unknown89Est. Sep 2021
NCT05977257Not Yet Recruiting89Est. Oct 2028
Boston Scientific
Boston ScientificCA - Valencia
2 programs
SentinelN/A1 trial
VIV TAVR with BVF using TCEPN/A1 trial
Active Trials
NCT05217888Completed158Est. May 2025
NCT05093764Recruiting20Est. Dec 2025
Foldax
FoldaxUT - Salt Lake City
1 program
Foldax Tria Aortic ValveN/A1 trial
Active Trials
NCT03851068Active Not Recruiting40Est. Dec 2026
Medtronic
MedtronicNJ - Phillipsburg
1 program
Medtronic Avalus UltraN/A1 trial
Active Trials
NCT06506903Active Not Recruiting190Est. Nov 2026
Terumo Medical
Terumo MedicalGermany - Leverkusen
1 program
Neurocognitive Assessment in TAVIN/A1 trial
Active Trials
NCT06120946Completed120Est. Dec 2022
Novostia
NovostiaSwitzerland - Lausanne
1 program
TRIFLO Heart ValveN/A1 trial
Active Trials
NCT06119607Active Not Recruiting10Est. Jun 2029
Cardiawave
CardiawaveFrance - Levallois-Perret
1 program
Valvosoft TreatmentN/A1 trial
Active Trials
NCT07520591Not Yet Recruiting200Est. Jun 2028
Venus MedTech
Venus MedTechChina - Hangzhou
1 program
Venus-Neo Surgical Aortic ValveN/A1 trial
Active Trials
NCT05941455Not Yet Recruiting155Est. Oct 2029
LSI Solutions
LSI SolutionsNY - Victor
1 program
automated annular suturingN/A1 trial
Active Trials
NCT04659655Unknown30Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Edwards LifesciencesAspirin
ArtivionOn-X Aortic Mechanical Valve
CardiawaveValvosoft Treatment
Edwards LifesciencesEdwards INSPIRIS RESILIA Aortic Valve
CorcymPerceval S sutureless heart valve
MedtronicMedtronic Avalus Ultra
NovostiaTRIFLO Heart Valve
Venus MedTechVenus-Neo Surgical Aortic Valve
Edwards LifesciencesJ-Valve TF System
MicroPortVitaFlow® Transcatheter Aortic Valve Replacement System
Boston ScientificSentinel
Boston ScientificVIV TAVR with BVF using TCEP
AbbottVAVGJ
Terumo MedicalNeurocognitive Assessment in TAVI
LSI Solutionsautomated annular suturing

Showing 15 of 34 trials with date data

Clinical Trials (35)

Total enrollment: 11,046 patients across 35 trials

NCT01559298Edwards LifesciencesAspirin

Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial

Start: Mar 2012Est. completion: Mar 2016178 patients
Phase 4Completed
NCT04142658ArtivionOn-X Aortic Mechanical Valve

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Start: May 2020Est. completion: Dec 2022863 patients
Phase 3Terminated
NCT03876964Edwards LifesciencesTranscatheter Aortic Valve Replacement

J-Valve Compassionate Use

N/ANo Longer Available
NCT07520591CardiawaveValvosoft Treatment

Valvosoft Outcomes Registry for Real-World Evidence

Start: May 2026Est. completion: Jun 2028200 patients
N/ANot Yet Recruiting
NCT07120048Edwards LifesciencesEdwards INSPIRIS RESILIA Aortic Valve

Real World Data Collection on the INSPIRIS RESILIA Aortic Valve

Start: Jul 2025Est. completion: Dec 2026500 patients
N/ARecruiting
NCT06011148CorcymPerceval S sutureless heart valve

Clinical Data Collection on Perceval S Sutureless Prosthetic Aortic Valve in the Chinese Population

Start: Dec 2024Est. completion: Dec 202580 patients
N/AUnknown
NCT06506903MedtronicMedtronic Avalus Ultra

Avalus Ultra Post-Approval Study (PAS)

Start: Nov 2024Est. completion: Nov 2026190 patients
N/AActive Not Recruiting
NCT06119607NovostiaTRIFLO Heart Valve

PILot Aortic Triflo Valve Study

Start: Nov 2023Est. completion: Jun 202910 patients
N/AActive Not Recruiting
NCT05941455Venus MedTechVenus-Neo Surgical Aortic Valve

A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve

Start: Oct 2023Est. completion: Oct 2029155 patients
N/ANot Yet Recruiting
NCT06034028Edwards LifesciencesJ-Valve TF System

J-Valve TF Early Feasibility Study

Start: Oct 2023Est. completion: Aug 202925 patients
N/AActive Not Recruiting
NCT05977257MicroPortVitaFlow® Transcatheter Aortic Valve Replacement System

VitaFlow® Transcatheter Aortic Valve Replacement System Pre-market Trial Long Term Follow Up （VITAL）

Start: Jul 2023Est. completion: Oct 202889 patients
N/ANot Yet Recruiting
NCT05217888Boston ScientificSentinel

The Sentinel Registry

Start: May 2022Est. completion: May 2025158 patients
N/ACompleted
NCT05093764Boston ScientificVIV TAVR with BVF using TCEP

Quantification of Debris Captured Using TCEP During VIV TAVR With BVF

Start: Mar 2022Est. completion: Dec 202520 patients
N/ARecruiting
NCT04754217AbbottVAVGJ

Valved Graft PMCF Study

Start: Jul 2021Est. completion: Sep 2029260 patients
N/ARecruiting
NCT06120946Terumo MedicalNeurocognitive Assessment in TAVI

Neurocognitive Assessment in TAVI

Start: May 2021Est. completion: Dec 2022120 patients
N/ACompleted
NCT04659655LSI Solutionsautomated annular suturing

VIenna Pilot Study for Automated Annular Suturing Technology

Start: Jan 2021Est. completion: Mar 202230 patients
N/AUnknown
NCT03924661AbbottAortic Valve Replacement

SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy

Start: Oct 2019Est. completion: Oct 202820 patients
N/AActive Not Recruiting
NCT03851068FoldaxFoldax Tria Aortic Valve

Early Feasibility Study for the Foldax Tria Aortic Heart Valve

Start: Jun 2019Est. completion: Dec 202640 patients
N/AActive Not Recruiting
NCT03481387CorcymAortic Valve Replacement with Perceval S sutureless heart valve

PERCEVAL S Valve Clinical Study for Chinese Registration

Start: Jan 2018Est. completion: Feb 202461 patients
N/AUnknown
NCT03016169AbbottTrifecta GT

Trifecta™ GT Post Market Clinical Follow-up

Start: Mar 2017Est. completion: Aug 2023358 patients
N/ACompleted
NCT02673697CorcymPerceval valve

Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement

Start: Mar 2016Est. completion: Jul 2020914 patients
N/ATerminated
NCT02907463Edwards LifesciencesEDWARDS INTUITY Elite Valve System

EDWARDS INTUITY Elite Valve System

Start: Feb 2016Est. completion: Dec 2017280 patients
N/ACompleted
NCT02679404CorcymSorin Universal REgistry on Aortic Valve Replacement

Sorin Universal REgistry on Aortic Valve Replacement

Start: May 2015Est. completion: Mar 20212,758 patients
N/ATerminated
NCT02458560Edwards LifesciencesEdwards CENTERA Self-Expanding Transcatheter Heart Valve

CENTERA-2: Safety and Performance Study of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve

Start: Mar 2015Est. completion: Aug 2021203 patients
N/ACompleted
NCT02221921MicroPortMicroPort's Transcatheter Aortic Valve and Delivery System

Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI

Start: Sep 2014Est. completion: Sep 202189 patients
N/AUnknown
NCT03025971Edwards LifesciencesJ-Valve Transcatheter Aortic valve replacement

Safety & Efficacy of the J-Valve Ausper System in Patients With Severe Aortic Stenosis and/or Aortic Regurgitation

Start: Mar 2014Est. completion: Apr 2020107 patients
N/ACompleted
NCT01808274Edwards LifesciencesEdwards CENTERA Self-Expanding Transcatheter Heart Valve

Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve

Start: Feb 2013Est. completion: Aug 201834 patients
N/ACompleted
NCT01808287Edwards LifesciencesEdwards SAPIEN 3 Transcatheter Heart Valve

Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve/ The SAPIEN 3 Study

Start: Jan 2013Est. completion: Dec 2019250 patients
N/ACompleted
NCT02688153Edwards LifesciencesEDWARDS INTUITY

EDWARDS INTUITY Valve System CADENCE Study

Start: Oct 2012Est. completion: Apr 2016120 patients
N/ACompleted
NCT02981004AbbottPAR I - Patient-to-Annulus Relation I

PAR I - Patient-to-Annulus Relation I

Start: Oct 2012Est. completion: Dec 2017304 patients
N/ACompleted
NCT02338154Edwards LifesciencesEDWARDS INTUITY Valve System FOUNDATION Study

EDWARDS INTUITY Valve System FOUNDATION Study

Start: Jul 2012Est. completion: Apr 2016516 patients
N/ACompleted
NCT02672553Edwards LifesciencesEDWARDS INTUITY Valve System, Model 8300A

EDWARDS INTUITY Valve System CADENCE-MIS Study

Start: May 2012Est. completion: Aug 2015100 patients
N/ACompleted
NCT01256710AbbottTrifecta™ aortic bioprosthesis

Trifecta™ Durability Study

Start: Jan 2011Est. completion: Mar 20211,151 patients
N/ATerminated
NCT00465218Edwards LifesciencesProphylaxis of Thrombosis after aortic valve replacement

Transcranial Doppler (TCD) Assessment During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement

Start: Mar 2007Est. completion: Mar 201156 patients
N/ACompleted
NCT00590889AbbottArtificial Mechanical Heart Valve

Artificial Valve Endocarditis Reduction Trial

Start: Jul 1998Est. completion: Sep 2014807 patients
N/ATerminated

Related Jobs in Cardiovascular

Senior Manufacturing Engineer

BALTBALT
Irvine, California, United States
13h ago
$120K - $130K/yr

Staff Product Development Engineer

Jupiter EndovascularJupiter Endovascular
Menlo Park, CA
15h ago
$160K - $180K/yr

Application Security Engineer

HeartFlowHeartFlow
San Francisco, California
16h ago
$145K - $180K/yr

Senior Software Engineer

HeartFlowHeartFlow
San Francisco, California, United States
16h ago
$180K - $215K/yr

Staff Software Engineer

HeartFlowHeartFlow
San Francisco, California
16h ago
$190K - $250K/yr

Director, Clinical Quality Lead

KardiganKardigan
South San Francisco, California, United States, Princeton, New Jersey, United States
20h ago
$194K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 11,046 patients
14 companies competing in this space

Related Indications

Hypertension(936)Heart Failure(877)Coronary Artery Disease(769)Atrial Fibrillation(615)Pulmonary Arterial Hypertension(207)Acute Coronary Syndrome(140)Atherosclerosis(123)Aortic Valve Stenosis(121)Pulmonary Hypertension(111)Congestive Heart Failure(94)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.